调强放疗联合肝动脉化疗栓塞术治疗原发性肝癌患者的效果

Effects of intensity modulated radiotherapy combined with hepatic arterial chemoembolization in treatment of patients with primary liver cancer

目的:观察调强放疗联合肝动脉化疗栓塞术治疗原发性肝癌患者的效果。方法:选取94例原发性肝癌患者为研究对象,按照随机数字表法分为对照组和观察组各47例。对照组采用肝动脉化疗栓塞术治疗,观察组在对照组的基础上联合调强放疗,比较两组临床疗效、治疗前后生命质量[简明健康状况调查表(SF-36)]评分、1年生存率及不良反应发生率。结果:观察组缓解率为80.85%,高于对照组的61.70%,差异有统计学意义(P<0.05);治疗后,观察组SF-36评分高于对照组,差异有统计学意义(P<0.05);观察组1年生存率为82.98%,高于对照组的63.83%,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:调强放疗联合肝动脉化疗栓塞术治疗原发性肝癌患者可提高缓解率和1年生存率,改善患者生命质量,且安全性较高,其效果优于单纯肝动脉化疗栓塞治疗。

Objective:To observe effects of intensity modulated radiotherapy combined with hepatic arterial chemoembolization in treatment of patients with primary liver cancer.Methods:94 patients with primary liver cancer were selected as the research objects,and were divided into control group and observation group according to the random number table method,47 cases in each group.The control group was treated with hepatic arterial chemoembolization,while the observation group was combined with intensity-modulated radiotherapy on the basis of that of the control group.The clinical efficacy,the quality of life[short form health status questionnaire(SF-36)]score,the 1-year survival rate and the incidence of adverse reactions before and after the treatment were compared between the two groups.Results:The remission rate of the observation group was 80.85%,which was higher than the control group of 61.70%,and the difference was statistically significant(P<0.05).After the treatment,the SF-36 score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The 1-year survival rate of the observation group was 82.98%,which was higher than the control group of 63.83%,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Intensity-modulated radiotherapy combined with hepatic arterial chemoembolization in the treatment of the patients with primary liver cancer can increase the remission rate and the 1-year survival rate,improve the quality of life,and has high safety.Moreover,it is superior to single hepatic arterial chemoembolization.